Spyre Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Spyre Therapeutics (SYRE).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy

16Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$101Upside to Avg. PT+9.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	BTIG	Julian Harrison	Maintained	Buy	$121
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Buy	$120
Oct 1, 2026	JP Morgan	Hardik Parikh	Initiate	Overweight	$110
Oct 1, 2026	BTIG	Julian Harrison	Maintained	Buy	$121
Sep 9, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$123
Sep 8, 2026	BTIG	Julian Harrison	Maintained	Buy	$121
Aug 26, 2026	Deutsche Bank	David Hoang	PT Cut	Buy	$135→$127
Aug 26, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$130→$123
Aug 26, 2026	BTIG	Julian Harrison	PT Cut	Buy	$132→$121
Aug 11, 2026	BTIG	Julian Harrison	PT Raise	Buy	$112→$132
Aug 5, 2026	Wells Fargo	Yanan Zhu	PT Raise	Overweight	$90→$115
Aug 5, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$115→$130
Aug 5, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$100→$130
Jul 28, 2026	Wolfe Research	Andy Chen	Downgrade	Outperform→Peer Perform	—
Jul 13, 2026	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$84→$120
Jun 23, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$115→$135
Jun 15, 2026	BTIG	Julian Harrison	PT Raise	Buy	$98→$112
Jun 4, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$102→$115
May 6, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$64→$97
May 6, 2026	Stifel	Alex Thompson	PT Raise	Buy	$92→$107

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

UBS analyst Alice Nettleton initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

JP Morgan analyst Hardik Parikh initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Overweight rating and announces Price Target of $110.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.

Benzinga Newsdesk

Spyre Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Spyre Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

PRO
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

People Also Watch

People Also Watch

Spyre Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Spyre Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PROUBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

PROJP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

PROBTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PROWedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

PROBTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

PRO
JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

PRO
Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target

PRO
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target